Introduction
Transforming growth factor-b (TGF-b) is a multifunctional cytokine, which serves as a potent growth inhibitor of epithelial cells, endothelial cells, hematopoietic cells, and lymphocytes. TGF-b also induces epithelial-mesenchymal transition (EMT), and facilitates the deposition of extracellular matrix (ECM) proteins. TGF-b has two distinct and opposite roles in cancer progression and metastasis. TGF-b suppresses tumor cell growth during the early stages of carcinogenesis. However, in advanced tumors, tumor cells often become refractory to TGF-b-mediated growth inhibition and overexpress TGF-b, which induces EMT and invasion of tumor cells and facilitates immunosuppression, deposition of ECM, and angiogenesis (Derynck et al., 2001) . Three isoforms of TGF-b, termed TGF-b1, -b2 and -b3, with similar structures and biological activities in vitro have been identified in mammals. TGF-bs belong to a large superfamily, termed the TGF-b superfamily, which includes TGF-bs, activins, myostatin, bone morphogenetic proteins (BMPs), growth/ differentiation factors and anti-Mu¨llerian hormone (AMH) (Miyazawa et al., 2002) .
Members of the TGF-b superfamily exert their biological effects by interacting with two types of cell surface receptors, termed type II and type I, with intrinsic serine/threonine kinase activities (Heldin et al., 1997) . The receptor activation mechanism for TGF-b involves initial binding of ligand to its type II receptor (TbR-II), which leads to recruitment, phosphorylation and activation of type I receptor (TbR-I), followed by activation of intracellular signaling. TbR-II is the primary ligand-binding protein and can bind ligand with high affinity in the absence of TbR-I. In contrast, TbR-I is unable to bind ligand in the absence of TbR-II. Upon binding of TGF-b to TbR-II and TbR-I, TbR-II transphosphorylates the GS domain of TbR-I, resulting in the activation of TbR-I kinase. The type II and type I receptors form hetero-oligomers composed of multiple type II and type I receptor molecules (Yamashita et al., 1994; Hart et al., 2002) . In addition to TbR-I (also termed activin receptor-like kinase (ALK)-5), which is ubiquitously expressed and transduces typical TGF-b signals, another type I receptor termed ALK-1, which is specifically expressed in endothelial cells, also serves as a type I receptor for TGF-b, although ALK-1 transduces signals distinct from those induced by TbR-I/ALK-5 (Oh et al., 2000; Goumans et al., 2003) . On the other hand, only one type II receptor for TGF-b (TbR-II) is present in mammals. Thus, dissecting the structural basis for the high-affinity interaction between TGF-b and TbR-II is fundamentally important to understand the initial molecular events in the activation of TGF-b signaling pathways. It will also provide useful molecular designing strategies for modulation of the many important effects of TGF-b.
A number of mutagenesis studies of TGF-b have led to the identification of several amino-acid residues, including R94 of TGF-b1, implicated in binding of TGF-b to TbR-II (Qian et al., , 1999 . The threedimensional structures of TGF-bs (Daopin et al., 1992; Schlunegger and Grutter, 1992; Hinck et al., 1996; Mittl et al., 1996) provide opportunities for examining the structural differences between the isoforms at the molecular level and the basis for analysis of the interactions of the ligands with the receptors. In addition, recently reported crystal structure data have greatly advanced understanding of how members of the TGF-b superfamily interact with their receptors (Kirsch et al., 2000; Hart et al. 2002; Greenwald et al., 2003; Thompson et al., 2003; Allendorph et al., 2006) . The crystal structure of the TbR-II extracellular domain-TGF-b3 complex showed that two arginine residues, R25 and R94, of TGF-b3 are involved in the formation of hydrogen-bonded ion pairs with TbR-II extracellular domain residues E142 and D55, respectively (Hart et al., 2002) .
According to the crystal structure of the TbR-II-TGF-b3 complex reported by Hart et al. (2002) , we have also predicted a number of hypothetical ligand-binding sites on the TbR-II surface. To verify the function of these residues on the TbR-II surface, we introduced mutations into these sites, and examined the abilities of these mutants for ligand binding as well as intracellular signaling. Furthermore, we screened chemical compounds that prevent the interaction between TGF-b and TbR-II, and found that 3,5,7,2 0 ,4 0 -pentahydroxyflavone (Morin) inhibits TGF-b binding to TbR-II and suppresses intracellular signaling.
Results

D55
and E142 are critical binding sites for TGF-b on the TbR-II surface Hart et al. (2002) reported the crystal structure of the TbR-II extracellular domain-TGF-b3 complex and showed that TbR-II extracellular domain residues D55 and E142 are involved in the binding to TGF-b3. Interestingly, D55 is found in BMPR-II but not in the other type II receptors, whereas E142 is conserved only in TbR-II (Figure 1a) , suggesting the importance of the specific interaction between TbR-II and TGF-b. Here, we mutated D55 and E142 of TbR-II individually or in combination, and evaluated the ligand-binding properties of the TbR-II mutants. We studied the ligandbinding properties of the TbR-II mutants in COS7 cells by affinity cross-linking, followed by immunoprecipitation of TbR-II by a FLAG antibody. We also examined the expression levels of the TbR-II mutants simultaneously. As the side chains of these mutated residues are predicted to be exposed at the protein surface, the risk of introducing significant conformational changes upon mutation may be low. However, compared to the wildtype TbR-II, TbR-II mutants were less efficiently transported to the cell surface. Therefore, we modified the amounts of transfected cDNAs to obtain similar expression levels of the wild-type and TbR-II mutants on the cell surface. As shown in Figure 1b , the ligandbinding abilities of D55A and E142A mutants were less than that of wild-type TbR-II, and TGF-b1 bound to the receptor was scarcely detectable in the D55A/E142A double mutant.
We further investigated intracellular signaling activities of the TbR-II double mutant. The D55A/E142A mutant was transiently transfected into the DR mutant of Mv1Lu cells that lack functional TbR-II and transcriptional activity was determined using p3TP-Lux. In the absence or presence of a low dose (0.03 ng/ ml) of TGF-b1, the D55A/E142A mutant induced lower transcriptional activity than did the wild-type TbR-II (Figure 1c) . However, similar levels of transcriptional activities were observed in both wild-type and the D55A/E142A mutant in the presence of 1 ng/ml of TGF-b1 (Figure 1c) .
The activation of TGF-b receptors is thought to be initiated by initial binding of TGF-b to TbR-II, which leads to subsequent recruitment, phosphorylation and activation of the type I receptor. We had so far examined only the interaction between TGF-b and TbR-II, but not the binding of TGF-b to TbR-II in the presence of TbR-I. We therefore performed affinity cross-linking experiments using the D55A/E142A mutant in the presence of TbR-I (Figure 1d ). When the D55A/E142A TbR-II mutant alone was transfected into COS7 cells, no significant binding of ligand to the receptor was detected. However, when the D55A/E142A TbR-II mutant and TbR-I were co-transfected, TGF-b was able to bind to TbR-I as well as to the TbR-II mutant weakly. These results suggest that TbR-I and TbR-II form a complex when they are overexpressed, and that TGF-b binds weakly to the TbR-ITbR-II complex, even though TGF-b cannot bind to TbR-II.
E98 of TbR-II is also important for ligand binding
To determine additional ligand-binding sites of TbR-II, we further investigated the roles of other amino-acid residues. In addition to D55, a number of hypothetical binding sites on the TbR-II extracellular domain surface was predicted, including seven charged residues R57, D62, K65, R89, D92, E98 and D103 in human TbR-II (Figure 2a) . Thus, we mutated individually the seven charged amino acid residues. In addition, three noncharged residues S59, N63 and N91 and one hydrophobic residue V100 of TbR-II, which are located in the vicinity of D55 and other hypothetical ligandbinding sites, and are potentially involved in the interaction with TGF-b, were also mutated. The amounts of transfected cDNAs were modified to obtain similar expression levels of the wild-type and TbR-II mutants on the cell surface.
Similar levels of cross-linked ligand-receptor complexes were detected for the wild-type TbR-II and the 10 mutants targeting hydrophobic and hydrophilic residues, including R57, S59, D62, N63, K65, R89, N91, D92, V100 and D103 (Figure 2b and data not shown). In contrast, the ligand-binding ability of TbR-II mutants on E98 was diminished similar to D55, although these mutants were expressed on the cell surface at approximately the same level as TbR-II ( Figure 2b , lower panels). However, a number of experiments showed that the contribution of D55 to ligand binding was larger than that of E98. In contrast to the single amino acid mutants, the D55A/E98Q double mutant was expressed at a very low level (Figure 2c ), suggesting that at least one of the two amino-acid residues plays an important role in structural folding or stability of TbR-II. Interestingly, E98 is not conserved in other type II receptors (see Figure 1a ). These findings suggest that in addition to D55 and E142, E98 may also be involved in the specific binding of TbR-II to its ligands.
Establishment of tetracycline (Tet)-inducible expression system of the wild-type or D55A/E142A mutant TbR-II Although TbR-I has been reported to be unable to bind TGF-b in the absence of TbR-II, TbR-I enhanced binding of ligands to the D55A/E142A TbR-II mutant. In addition, luciferase reporter gene transcription was strongly activated by 1 ng/ml of TGF-b1 in the presence of the D55A/E142A mutant TbR-II. It is possible that transiently overexpressed receptors stimulated the formation of ligand-receptor complexes and activated downstream signals. To verify whether these phenomena are also observed at physiological expression levels of TbR-II, we generated DR mutant cell clones expressing the wild-type or mutant TbR-II in a Tet-regulated manner. As TGF-b signals suppress cell proliferation, the expression levels of TbR-II should be controlled at a low level under basal conditions, and therefore we utilized a Tet-regulated expression system.
In order to generate parental cell lines (Tet-Parental), a CAG promoter-driven Tet transactivator (tTA) was introduced into DR mutant cells. The expression of TbR-II is driven by a Tet-regulated promoter, which is suppressed by the addition of Tet (Tet-off-system). The expression of TbR-II is suppressed in the presence of Tet and activated when Tet is removed. A number of cell clones were established by transfection and double drug selection (see Materials and methods), and analysed for their ability to express TbR-II. A parental control clone did not express the TbR-II protein in the presence or absence of Tet. While transfected clones had only a minimal basal level of TbR-II expression in the presence of Tet, they expressed TbR-II after Tet removal as determined by affinity cross-linking analysis and by immunoblot analysis with an anti-FLAG antibody. As shown in Figure 3a , wild-type clones #3 and #23 bound TGF-b1 in the absence of Tet, whereas D55A/ E142A mutant clones #33 and #42 failed to bind TGFb1 under the same condition. Levels of the expressed TbR-II protein in these clones were not varied and were similar to that of the original Mv1Lu cells in the presence of 30 ng/ml Tet (Figure 3b ). The D55A/E142A mutant protein in clone #42 migrated faster than the wild-type TbR-II protein (Figure 3a ), but treatment by N-glycosidase F revealed that this is due to the difference in glycosylation of the TbR-II proteins (data not shown). The Tet control system of these clones worked efficiently at all times during the culture, and therefore, we used these four clones in the following experiments.
The ligand-binding ability and dosage of TbR-II regulate the cell growth of Tet-inducible clones To define the functional significance of the inhibition of TGF-b1 binding to TbR-II at physiological expression levels, we determined the effect of D55A/E142A mutation in TbR-II on TGF-b1-induced growth inhibition of the mutant clone cells, as measured by 3 H-thymidine incorporation into cellular DNA. As proliferation of the parental control clone was not altered by TGF-b1 after the removal of Tet, all of the results described below were ascribed to Tet-regulated expression of TbR-II ( Figure 3c ). As shown in Figure 3d , growth of the D55A/E142A mutant clones #33 and #42 was affected only weakly by TGF-b1 in the absence of Tet in contrast to the wild-type clones #3 and #23. As these four clones expressed TbR-II at approximately the same level in the absence of Tet (Figure 3a) , clonal variation of the expression levels did not contribute to the differences in the cell growth between the wild-type and D55A/E142A mutant clones. Subsequently, we evaluated the quantitative effects of TbR-II on the growth inhibition by regulating the expression of the TbR-II protein. In the presence of 1 ng/ml TGF-b1, cell growth of the wild-type clones #3 and #23 was inhibited in a Tet dose-dependent manner, while that of the D55A/E142A mutant clones was not affected by addition of different concentrations of Tet (Figure 3e ). These results demonstrate that the dosage of TbR-II regulates cell proliferation in the cultures over the 24 h period and that D55 and E142 of TbR-II have crucial roles in signal transduction. 125 I-TGF-b1 was performed using transfected COS7 cells followed by FLAG immunoprecipitation of TbR-II-FLAG (upper panels). The middle panels demonstrate the levels of expression of transfected proteins. All of the mutants are expressed on the cell surface at approximately the same level as the wild-type TbR-II (lower panels). We mutated 12 residues individually in the full-length human TbR-II. The 125 I-TGF-b1-binding abilities of the TbR-II mutants, including D55, S59, D62, N63, E98 and D103, are shown in (b). The binding abilities of the other mutants, including R57, K65, R89, N91, D92 and V100, are not shown. Mutations in D55 to alanine (D55A) and to asparagine (D55N) essentially gave similar results to each other and those in E98 to alanine (E98A) and to asparagine (E98N) also gave similar results to each other.
Morin inhibits TGF-b binding to TbR-II and suppresses intracellular signal transduction As only two amino acid alterations at the position D55 and E142 of TbR-II remarkably diminished TGF-b binding, these sites are attractive targets for structurebased drug design. As D55 of TbR-II is critical for TGF-b binding, we attempted to design compounds that bind to the TbR-II active sites and inhibit downstream signaling activity utilizing structural information on modeled TbR-II. Approximately 190 000 commercially available chemicals were prefiltered to remove compounds with molecular masses >500 Da and docked into the binding site of the refined single TbR-II model using DOCK (Ewing, 1998) . Finally, 27 candidates were selected for in vitro screening on the basis of the docked score and visual inspection of the docked poses. From this approach, we found that Morin may inhibit TGF-bbinding to TbR-II.
We examined the effects of Morin on binding of biotin-labeled TGF-b1 to TbR-II/Fc chimera immobilized to ELISA plates. After incubation with biotin-labeled TGF-b1 (1 ng/ml) in the presence of various concentrations of Morin, TbR-II/Fc-associated signals were measured by a time-resolved fluorometer. As shown in Figure 4a I-labeled TGF-b1 (1 ng/ml) to normal human fibroblasts and the DR mutant clone expressing the wild-type TbR-II in a dose-dependent manner when determined by radio-receptor assay and cross-linking analysis, respectively (Figure 4b and c) .
Next, the effect of Morin on intracellular signaling induced by TGF-b was examined. Normal human fibroblasts were pretreated with various concentrations of Morin, and phosphorylation of TGF-b-specific Smad2 by TGF-b1 was analysed by immunoblotting using phospho-Smad2-specific antibody. As shown in Figure 4d , Morin inhibited the phosphorylation of Smad2 in a dose-dependent manner. Phosphorylation 
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of Smad2 was observed from 15 min after ligand stimulation, reached a maximal level at 1 h, and declined thereafter. Morin inhibited phosphorylation of Smad2 at every time point examined (Figure 4e) .
Finally, we have explored the effects of Morin on the transcriptional activity of TGF-b using human HaCaT keratinocytes. As shown in Figure 4f , TGF-b induced the transcription of Smad7 at 1 h, but this effect of TGF-b was significantly suppressed by Morin, although Morin was less effective than a small-molecule TbR-I kinase inhibitor SB-431542.
Discussion
By analysis of the crystal structure of the TGF-b3-TbR-II complex, Hart et al. (2002) demonstrated that the interaction surfaces are defined by pairs of charged amino acids that lie at the periphery of their binding sites: E142 and D55 in TbR-II, and R25 and R94 in TGF-b3. In the complex, TbR-II D55 pairs with TGF-b3 R94, and TbR-II E142 pairs with TGF-b3 R25 ( Figure 5 ). Our present study demonstrated that mutations in D55 and E142 of TbR-II In addition to D55 and E142, mutational analyses of TbR-II of other potential ligand-binding sites indicated that mutations of E98 of TbR-II result in a decrease in ligand binding. Although the contribution of D55 to ligand binding was larger than that of E98, E98 is located in the vicinity of D55, and it may thus participate in the binding of ligand to D55 of TbR-II. The three-dimensional model suggests that TbR-II E98 interacts with TbR-II D55 through a tightly bound water molecule that restricts the rotation of D55 ( Figure 5 ). During the preparation of this manuscript, De Crescenzo et al. (2006) reported that in addition to D55 and E142, I76, E78 and E98 are also involved in the binding of TbR-II to TGF-b. (Note that since Hart et al. (2002) and De Crescenzo et al. (2006) counted the amino acid numbers of the TbR-II protein without its signal peptide, D55, I76, E78, E98 and E142 were described as D32, I53, E55, E75 and E119, respectively, in their reports). However, they used soluble, extracellular domains of TbR-II, and determined the competition of these soluble TbR-II to the wild-type TbR-II in the binding of TGF-b.
Upon ligand binding and formation of type II and type I receptor complexes, conformational changes of the receptors may occur, and type I receptors are subsequently phosphorylated and activated by the type II receptor kinases. In the present study, we demonstrated that TbR-I stabilizes the complex formation between ligands and TbR-II, although TbR-I does not bind ligands in the absence of TbR-II. Functional binding sites for activin on the type I receptor have been reported, and predicted binding sites on TbR-I were discussed based on sequence similarity (Harrison et al., 2003) . However, analyses of the crystal structures revealed that ActR-IIB binds activin in a manner that differs from that of TGF-b3 binding to TbR-II (Thompson et al., 2003) . Thus, there may be additional TbR-I specific mechanisms that facilitate the complex formation. The diversity of cellular responses that can be induced by the interaction between TGF-bs and their receptors remains to be fully elucidated.
Although E142 of TbR-II is responsible for ligand binding, the amino acid residues surrounding E142 make the surface flat, and hence it is difficult to design low molecular mass compounds that inhibit the proteinprotein interaction including TbR-II E142. Thus, low molecular mass inhibitors primarily targeting D55 of TbR-II may bind more tightly to the TbR-II surface and be more effective in blocking the interaction between TGF-b and TbR-II.
Through screening of many commercially available chemicals based on the present findings and virtual screening techniques, we found that Morin, a naturally occurring flavonoid, is a candidate for binding to D55 of TbR-II. As shown in Figure 4 , Morin inhibited TGF-b binding to TbR-II and downstream signaling. Various naturally occurring flavonoids have been found to protect against cancer in chemically induced animal cancer models (Birt and Bresnick, 1990 ) and synthetic flavonoid derivatives are being tested as potential chemotherapeutic drugs in clinical trials (De Azevedo et al., 1996; Senderowicz, 1999; Kelland, 2000; Schwartz et al., 2001) . It has been suggested that Morin is a potent anti-hepatocellular transformation compound that inhibits cellular transformation by suppressing the AP-1 activity and inducing the S phase arrest in human hepatocytes (Hsiang et al., 2005) . Although relatively high concentrations of Morin are needed to inhibit TGF-b signaling, Morin may be valuable as a leading molecule to generate compounds with higher potency in inhibiting TGF-b ligand-receptor interaction.
As TGF-b is a potent inducer of tissue fibrosis, TGF-b antagonists have been generated to treat various fibrotic diseases. In addition, TGF-b inhibitors may be used to prevent invasion and metastasis of cancer, since TGF-b functions as a pro-oncogenic factor in advanced cancer. Small molecule inhibitors have been reported to be effective in inhibiting the TbR-I kinases (Bandyopadhyay et al., 2006) , although these small molecule inhibitors block not only the TbR-I/ALK-5 kinase but also related type I receptor kinases, that is ALK-4 and ALK-7 (Tojo et al., 2005) . Molecules that inhibit binding of TGF-bs to TbR-II may be useful because only one type II receptor for TGF-b is present in humans. Thus, our present findings on determination of functional ligand-binding sites on TbR-II may provide useful information for designing therapeutic agents for various diseases induced by TGF-b. 
Materials and methods
Construction of plasmids
The original constructions of TbR-I and TbR-II cDNAs, pcDNA3-FLAG and pcDEF3-HA were described previously (Imamura et al., 1997; Kawabata et al., 1998; Oeda et al., 1998) . All of the TbR-II mutants were prepared by a PCRbased approach. All of the PCR products were sequenced before use. Luciferase assay DR mutant Mv1Lu cells were transiently transfected with an appropriate combination of p3TP-lux promoter-reporter construct (Carcamo et al., 1994) , expression plasmids, and pcDNA3. Total amounts of transfected DNAs were the same in each experiment, and values were normalized using Renilla luciferase activity. Expression levels of all of the TbR-II proteins were determined by immunoblotting before use or in parallel with luciferase assays.
Immunoprecipitation and immunoblotting
Cells used in the present study were solubilized in a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1% aprotinin, and 1 mM phenylmethylsulfonyl fluoride. The cell lysates were precipitated by centrifugation and the supernatants were incubated with anti-FLAG M2 (SIGMA-Aldrich) antibody for 1 h, followed by incubation with protein A-or G-Sepharose beads. The beads were washed four times with the buffer used for cell solubilization. The immune complexes were then eluted by boiling for 3 min in sodium dodecyl sulfate (SDS) sample buffer (100 mM TrisHCl, pH 8.8, 0.01% bromophenol blue, 36% glycerol, 4% SDS, 10 mM DTT) and subjected to SDS-polyacryl amide gel electrophoresis (PAGE). Aliquots of the cell lysates were directly subjected to SDS-PAGE without immunoprecipitation. Proteins were electrotransferred to ProBlott membranes (Applied Biosystems, Foster City, CA, USA) and immunoblotted with anti-HA 3F10 (Boehringer, Mannheim, Germany), anti-FLAG M2, anti-phospho-Smad2 (Cell Signaling Technology, Danvers, MA, USA) or anti-Smad2 (Cell Signaling Technology) antibodies and detected using an ECL detection system (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Affinity cross-linking analysis Recombinant TGF-b1 (R&D Systems) was iodinated using the chloramine T method (Frolik et al., 1984) . Transfected COS7 cells or Tet-regulatable TbR-II clones were affinity crosslinked using 125 I-TGF-b1. Subsequent immunoprecipitation and analysis by SDS-PAGE were performed as previously described by Imamura et al. (1997) .
Biotinylation of cell surface receptors
Biotinylation of cell surface receptors was performed as described previously (Lopez-Casillas et al., 1993) . Cells were incubated with 1 mg/ml of sulfosuccinimidyl 6-(biotinamaide) hexanoate (NHS-LC-biotin, Pierce, Rockford, IL, USA) in phosphate-buffered saline for 1 h at 41C. Cells were then lysed and subjected to immunoprecipitation followed by SDS-PAGE. Cell surface receptors labeled with NHS-LC-biotin were detected with streptavidin conjugated to horseradish peroxidase using the ECL system.
Establishment of Tet-regulatory cell clones
The Tet-regulatory system was used to obtain DR mutant Mv1Lu cell clones expressing the wild-type and D55A/E142A mutant TbR-II. To establish a reliable parental DR Mv1Lu cell line expressing tTA (Baron et al., 1997) , tTA expression vectors pCAG 20-1 and pUHD10-3 Puro (Niwa et al., 1991; Era and Witte, 2000) were transfected into DR mutant Mv1Lu cells using Fugene6, and cells were grown with 2 mg/ml puromycin in Tet-free medium. Two parental clones proliferating in Tet-free medium, but dying in the presence of Tet, were selected as primary parental Tet-regulatory DR mutant Mv1Lu cells. The Tet-regulatable TbR-II construct, pUHD 10-3 TbR-II IRES GFP, was generated by inserting TbR-II into EcoRI and XbaI sites in pUHD10-3 IRES EGFP vector (Era and Witte, 2000) . One of the parental DR mutant Mv1Lu cell clones was transfected with pUHD 10-3 TbR-II IRES GFP vector and neomycin plasmid pMC1NEO (Stratagene, La Jolla, CA, USA). The cells were maintained in the presence of 1 mg/ml Tet and 1 mg/ml G418. Multiple neomycin resistant colonies from the parental clone were picked and clones tightly regulated by Tet were examined for TbR-II expression by immunoblotting under Tet þ and TetÀ conditions. Finally, a total of four Tet-regulatable TbR-II clones (two wild-type clones and two D55A/E142A mutant clones) were obtained.
Thymidine incorporation assay
Cells were seeded at a density of 2 Â 10 4 cells/well in 24-well plates and cultured overnight. The serum concentration in the medium was then decreased to 1%, and the cells were incubated for another 24 h, followed by stimulation with TGF-b1. At 24 h after stimulation, the cells were labeled with 3 H-thymidine for 4 h. Thymidine incorporation into the TCAinsoluble fraction was analysed as described previously (Ebisawa et al., 1999) .
Quantitative real-time PCR analysis
Total RNAs from HaCaT cells were extracted using the RNeasy Mini Kit (QIAGEN, Valencia, CA, USA). Firststrand cDNAs were synthesized using the SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) with oligo(dT) 20 primers. Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed using the 7500 Fast Real-Time PCR System (Applied Biosystems). The primer sequences used were as follows: human Smad7: forward 5 0 -CCTTAGCCGACT CTGCGAACTA, reverse 5 0 -CCAGATAATTCGTTCCCCC TGT; human b-actin: forward 5 0 -TCACCCACACTGTGCC CATCTACGA, reverse 5 0 -CAGCGGAACCGCTCATTGC CAATGG.
Reagents
Morin and SB-431542 were purchased from Sigma-Aldrich and stored as a solution in DMSO. This solution was used after diluting with the medium for each assay.
